Clincosm LogoSign in Get a demo

Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer

Sponsor
Maastricht Radiation Oncology (Other)
Overall Status
Recruiting
CT.gov ID
NCT01084785
Collaborator
Maastricht University Medical Center (Other)
10,000
Enrollment
1
Location
264
Duration (Months)
37.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine, by means of DNA and protein analysis, the relationship between DNA and protein profiles and a number of endpoints, which are important for the patient such as overall survival and side effects.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    It has already been known for a long time that cancer is a genetic disorder and that the development of the illness is a very complex interaction between genetic and surrounding factors. Also the response on therapy and the development and seriousness of side effects is stipulated by this complicated collaboration of genetic and surrounding factors. Moreover it is not only the DNA that plays an important role but also the systems of control at protein level. At this moment a lot of questions remain to be answered because up till now the studies were of rather restricted statistic strength with frequently inconsistent dates and moreover retrospective. Major retrospective studies are necessary to distinguish the relationship between DNA/protein patterns and clinical relevant endpoints like prognosis and toxicity in which an as broad as possible patient group is being monitored. For this reason we want to take blood samples in MAASTRO clinic of all patients with lung cancer and to store it encrypted so that we can perform DNA and protein analyses in future and to correlate the results with survival and toxicity of the treatment.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    10000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Storing Blood for Analysis of DNA and Protein of Patients With Cancer in MAASTRO Clinic
    Study Start Date :
    Jan 1, 2003
    Anticipated Primary Completion Date :
    Jan 1, 2025
    Anticipated Study Completion Date :
    Jan 1, 2025

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • cancer
      Exclusion Criteria:
      • not able to comply with follow-up

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Maastricht Radiation Oncology Maastricht Limburg Netherlands

      Sponsors and Collaborators

      • Maastricht Radiation Oncology
      • Maastricht University Medical Center

      Investigators

      • Principal Investigator: Dirk De Ruysscher, Prof PHD, CCMO

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      Maastricht Radiation Oncology
      ClinicalTrials.gov Identifier:
      NCT01084785
      Other Study ID Numbers:
      • 08-06-23/01
      • NCT00157352
      • NCT00157365
      • NCT00157391
      • NCT00157404
      • NCT00157417
      • NCT00157430
      • NCT00157443
      • NCT00157456
      • NCT00157469
      • NCT00157495
      • NCT00181337
      • NCT00181376
      • NCT00181389
      • NCT00181402
      • NCT00181415
      • NCT00181428
      • NCT00181441
      • NCT00181454
      • NCT00181467
      • NCT00181480
      • NCT00181493
      • NCT00181519
      • NCT01067872
      First Posted:
      Mar 11, 2010
      Last Update Posted:
      Apr 7, 2022
      Last Verified:
      Apr 1, 2022
      Keywords provided by Maastricht Radiation Oncology
      Cancer
      genomics
      proteomics

      Study Results

      No Results Posted as of Apr 7, 2022